000186247 001__ 186247
000186247 005__ 20241228120954.0
000186247 0247_ $$2doi$$a10.1007/s00259-022-06070-7
000186247 0247_ $$2pmid$$apmid:36474125
000186247 0247_ $$2ISSN$$a1619-7070
000186247 0247_ $$2ISSN$$a0340-6997
000186247 0247_ $$2ISSN$$a1432-105X
000186247 0247_ $$2ISSN$$a1619-7089
000186247 0247_ $$2altmetric$$aaltmetric:139890001
000186247 037__ $$aDKFZ-2022-03041
000186247 041__ $$aEnglish
000186247 082__ $$a610
000186247 1001_ $$0P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2$$aSachpekidis, Christos$$b0$$eFirst author$$udkfz
000186247 245__ $$aApplication of the long axial field-of-view PET/CT with low-dose [18F]FDG in melanoma.
000186247 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2023
000186247 3367_ $$2DRIVER$$aarticle
000186247 3367_ $$2DataCite$$aOutput Types/Journal article
000186247 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1677071903_29372
000186247 3367_ $$2BibTeX$$aARTICLE
000186247 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000186247 3367_ $$00$$2EndNote$$aJournal Article
000186247 500__ $$a#EA:E060#LA:E060# /   2023 Mar;50(4):1158-1167
000186247 520__ $$aThe recent introduction of long axial field-of-view (LAFOV) PET/CT scanners has yielded very promising results regarding image quality and sensitivity in oncological patients. We, herein, aim to determine an appropriate acquisition time range for the new long axial field of view Biograph Vision Quadra PET/CT (Siemens Healthcare) using low dose [18F]FDG activity in a group of melanoma patients.Forty-nine melanoma patients were enrolled in the study. All patients underwent total body PET/CT from the top of the head through the feet in two bed positions (field-of-view 106 cm) after i.v. injection of 2.0 MBq/kg [18F]FDG. The PET images of the first bed position (head to upper thigh; PET-10) were reconstructed and further split into 8-min (PET-8), 6-min (PET-6), 5-min (PET-5), 4-min (PET-4), and 2-min (PET-2) duration groups. Comparisons were performed between the different reconstructed scan times with regard to the visual evaluation of the PET/CT scans using the PET-10 images as reference and by calculating the 95%-CI for the differences between different time acquisitions. Moreover, objective evaluation of PET/CT image quality was performed based on SUV calculations of tumor lesions and background, leading to calculation of liver signal-to-noise ratio (SNR), and tumor-to-background ratio (TBR).A total of 60 scans were evaluated. Concerning visual analysis, 49/60 (81.7%) PET-10 scans were pathological, while the respective frequencies were 49/60 (81.7%) for PET-8 (95%-CI: - 0.0602-0.0602), 49/60 (81.7%) for PET-6 (95%-CI: - 0.0602-0.0602), 48/60 (80%) for PET-5 (95%-CI: - 0.0445-0.0886), 46/60 (76.7%) for PET-4 (95%-CI: - 0.0132-0.1370), and 45/60 (75%) for PET-2 (95%-CI: 0.0025-0.1593). In 18 PET-10 scans, the extent of metastatic involvement was very large, rendering the accurate calculation of [18F]FDG-avid tumor lesions very complicated. In the remaining 42 PET-10 scans, for which the exact calculation of tumor lesions was feasible, a total of 119 tumor lesions were counted, and the respective lesion detection rates for shorter acquisitions were as follows: 97.5% (116/119) for PET-8 (95%-CI: 0-1), 95.0% (113/119) for PET-6 (95%-CI: 0-1), 89.9% (107/119) for PET-5 (95%-CI: 0-2), 83.2% (99/119) for PET-4 (95%-CI: 1-2), and 73.9% (88/119) for PET-2 (95%-CI: 2-4). With regard to objective image quality evaluations, as a general trend, the reduction of acquisition time was associated with a decrease of liver SNR and a decrease of TBR, although in lesion-based analysis the change in TBR and tumor SUVmean values was non-significant up to 6 and 5 min acquisitions, respectively.In melanoma, low-dose LAFOV PET/CT imaging is feasible and can reduce the total scan time from head to upper thigh up to 5 min providing comparable diagnostic data to standard lengths of acquisition. This may have significant implications for the diagnostic work-up of patients with melanoma, given the need for true whole-body imaging in this type of cancer.
000186247 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000186247 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000186247 650_7 $$2Other$$aLAFOV PET/CT
000186247 650_7 $$2Other$$aMelanoma
000186247 650_7 $$2Other$$aSUV
000186247 650_7 $$2Other$$aTotal body
000186247 650_7 $$2Other$$aWhole-body
000186247 650_7 $$2Other$$a[18F]FDG
000186247 7001_ $$0P:(DE-He78)96ac0342a3ccf9553e3d4c9da9b821b0$$aPan, Leyun$$b1$$udkfz
000186247 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, Annette$$b2$$udkfz
000186247 7001_ $$0P:(DE-He78)7dc85735e114a4ace658ba1450a2cca6$$aWeru, Vivienn$$b3$$udkfz
000186247 7001_ $$aHassel, Jessica C$$b4
000186247 7001_ $$0P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDimitrakopoulou-Strauss, Antonia$$b5$$eLast author$$udkfz
000186247 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-022-06070-7$$n4$$p1158-1167$$tEuropean journal of nuclear medicine and molecular imaging$$v50$$x1619-7070$$y2023
000186247 8767_ $$8V52536$$92023-12-01$$d2024-12-27$$eHybrid-OA$$jZahlung erfolgt
000186247 909CO $$ooai:inrepo02.dkfz.de:186247$$pVDB$$pOpenAPC$$popenCost
000186247 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000186247 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)96ac0342a3ccf9553e3d4c9da9b821b0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000186247 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000186247 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7dc85735e114a4ace658ba1450a2cca6$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000186247 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000186247 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000186247 9141_ $$y2022
000186247 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-23$$wger
000186247 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-23$$wger
000186247 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-23
000186247 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-23
000186247 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2022$$d2023-08-23
000186247 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-23
000186247 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-23
000186247 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-23
000186247 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-23
000186247 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-23
000186247 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-23
000186247 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-23
000186247 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-23
000186247 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2022$$d2023-08-23
000186247 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000186247 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000186247 9202_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x0
000186247 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x0
000186247 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000186247 9200_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x0
000186247 980__ $$ajournal
000186247 980__ $$aVDB
000186247 980__ $$aI:(DE-He78)E060-20160331
000186247 980__ $$aI:(DE-He78)C060-20160331
000186247 980__ $$aUNRESTRICTED
000186247 980__ $$aAPC